AB
BBIO icon

Amalgamated Bank’s BridgeBio Pharma BBIO Stock Holding History

Amalgamated Bank’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$883K Buy
11,849
+6,863
+138% +$481K 0.01% 1154
2026
Q1 		$370K Hold
4,986
– – ﹤0.01% 1416
2025
Q4 		$381K Buy
4,986
+106
+2% +$6.96K ﹤0.01% 1415
2025
Q3 		$253K Hold
4,880
– – ﹤0.01% 1510
2025
Q2 		$211K Hold
4,880
– – ﹤0.01% 1537
2025
Q1 		$169K Buy
4,880
+17
+0.3% +$573 ﹤0.01% 1570
2024
Q4 		$133K Hold
4,863
– – ﹤0.01% 1656
2024
Q3 		$124K Hold
4,863
– – ﹤0.01% 1668
2024
Q2 		$123K Buy
4,863
+962
+25% +$26.3K ﹤0.01% 1674
2024
Q1 		$121K Sell
3,901
-10,527
-73% -$358K ﹤0.01% 1691
2023
Q4 		$582K Sell
14,428
-1,347
-9% -$40.5K ﹤0.01% 1387
2023
Q3 		$416K Buy
15,775
+576
+4% +$16.3K ﹤0.01% 1501
2023
Q2 		$261K Buy
15,199
+1,901
+14% +$28.6K ﹤0.01% 1714
2023
Q1 		$220K Sell
13,298
-2,178
-14% -$25.4K ﹤0.01% 1763
2022
Q4 		$118K Hold
15,476
– – ﹤0.01% 2073
2022
Q3 		$154K Buy
15,476
+165
+1% +$1.71K ﹤0.01% 1949
2022
Q2 		$139K Sell
15,311
-483
-3% -$4.04K ﹤0.01% 2036
2022
Q1 		$160K Sell
15,794
-1,398
-8% -$14.3K ﹤0.01% 2025
2021
Q4 		$287K Sell
17,192
-285
-2% -$12.1K ﹤0.01% 1846
2021
Q3 		$819K Sell
17,477
-1,133
-6% -$60.7K 0.01% 1343
2021
Q2 		$1.13M Buy
18,610
+5,217
+39% +$298K 0.01% 1231
2021
Q1 		$825K Buy
13,393
+2,011
+18% +$132K 0.03% 688
2020
Q4 		$809K Buy
11,382
+57
+0.5% +$2.75K 0.03% 684
2020
Q3 		$425K Sell
11,325
-333
-3% -$10.5K 0.02% 927
2020
Q2 		$380K Sell
11,658
-1,381
-11% -$42.1K 0.02% 981
2020
Q1 		$378K Buy
+13,039
New +$404K 0.01% 1036

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Amalgamated Bank's BBIO Position: Q2 2026 in Review

Amalgamated Bank increased its BridgeBio Pharma (BBIO) stake by 138% in Q2 2026, buying an estimated $481K and bringing the position to 11,849 shares worth $883K. The position accounts for 0.01% of the portfolio, ranked #1154.

Amalgamated Bank first reported a position in BBIO in Q1 2020 and has held it in 26 quarters since. The position peaked at $1.13M in Q2 2021. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Amalgamated Bank held 11,849 shares of BridgeBio Pharma worth $883K as of Q2 2026.
  • Amalgamated Bank bought 6,863 BridgeBio Pharma shares in Q2 2026, an estimated $481K.
  • BridgeBio Pharma made up 0.01% of Amalgamated Bank's portfolio in Q2 2026, its #1154 holding.
  • Amalgamated Bank first reported a position in BridgeBio Pharma in Q1 2020 and has held it in 26 quarters since.
  • Amalgamated Bank's BridgeBio Pharma position peaked at $1.13M in Q2 2021.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Amalgamated Bank's 13F filing for Q2 2026, filed 23 Jul 2026.